Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with
distinct biology compared to other kidney cancer subtypes. The heterogeneity between the …

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Highlights•This special article provides key recommendations on the immunotherapy
treatments of renal cell carcinoma.•Recommendations are based on available scientific data …

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …

Aim To update the recommendations for the management of kidney cancers. Methods A
systematic review of the literature was conducted from 2015 to 2022. The most relevant …

PURPOSE COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid
tumors. We report results from patients with advanced clear cell (cc) and non–clear cell (ncc) …

Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on
the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with …

PURPOSE Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments
are required. There is a strong rationale for investigating mesenchymal epithelial transition …

In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has
remarkably improved following the advent of the “targeted therapy” era. The expanding …

Background We previously reported on a phase 2 study of everolimus plus bevacizumab
across various nonclear cell renal cell carcinoma (nccRCC) histologies and observed …